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Abstract: Starting in 2006, bluetongue virus serotype 8 (BTV8) was responsible for a major epizootic in
Western and Northern Europe. The magnitude and spread of the disease were surprisingly high and
the control of BTV improved significantly with the marketing of BTV8 inactivated vaccines in 2008.
During late summer of 2011, a first cluster of reduced milk yield, fever, and diarrhoea was reported in
the Netherlands. Congenital malformations appeared in March 2012 and Schmallenberg virus (SBV)
was identified, becoming one of the very few orthobunyaviruses distributed in Europe. At the start
of both epizootics, little was known about the pathogenesis and epidemiology of these viruses in the
European context and most assumptions were extrapolated based on other related viruses and/or
other regions of the World. Standardized and repeatable models potentially mimicking clinical signs
observed in the field are required to study the pathogenesis of these infections, and to clarify their
ability to cross the placental barrier. This review presents some of the latest experimental designs
for infectious disease challenges with BTV or SBV. Infectious doses, routes of infection, inoculum
preparation, and origin are discussed. Particular emphasis is given to the placental crossing associated
with these two viruses.
Keywords: Bluetongue; Schmallenberg; Culicoides; vector-borne disease; experimental challenge;
infection; arboviruses
1. Introduction
Amongst pathogens, RNA viruses were a major source of emerging diseases during the last 30
years [1]. High mutation rate and in case of segmented genome, reassortment are responsible for
genetic adaptability and variability of these viruses.
Two pathogens affecting cattle and sheep were responsible for major outbreaks in Mainland
Europe in the past 15 years: Bluetongue virus (BTV) and Schmallenberg virus (SBV). These outbreaks
were singular in several ways: the diseases were previously either never reported in such northern
locations (bluetongue virus) or recently discovered (Schmallenberg virus); their emergence still has
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unexplained aspects; both viruses displayed the ability to cross the placental barrier. Moreover, these
events confirmed that palearctic endemic Culicoides species contribute to the spread of BTV and SBV
and to the epizootic aspect of the diseases.
Bluetongue virus causes the eponymous bluetongue disease (BT). BTV belongs to the family
Reoviridae, subfamily Sedoreovirinae, and represents the type specie of the Orbivirus genus [2]. The family
Reoviridae currently contains fifteen genera of multi-segmented dsRNA viruses, including pathogens of
a wide range of vertebrates (including humans), arthropods, plants, and fungi [3]. Unlike the other
reoviruses, all orbiviruses are arthropod-borne viruses (arboviruses). This genus currently contains 22
species as well as 10 unclassified “orbiviruses” [4].
Until recent nomenclature changes implemented by the International Committee on Taxonomy
of Viruses [5] Schmallenberg virus was part of the Bunyaviridae family, genus Orthobunyavirus,
grouped within the serogroup Simbu along with at least 27 other virus species. The members of
the Simbu serogroup show cross-reactions to the complement fixation test but are distinguished by
seroneutralization [6] and by genetic sequence analysis. Yet still part of the Orthobunyavirus genus,
SBV, AKAV and Aino virus (AINOV) are now considered exemplar viruses of the species Sathuperi
orthobunyavirus, Akabane orthobunyavirus, and Shuni orthobunyavirus, respectively [7]. These belong to
the new order Bunyavirales, family Peribunyaviridae (formerly Bunyaviridae), which comprises the genus
Orthobunyavirus and Herbevirus (host range limited to insects).
Despite their belonging to different viral families, BTV and SBV have several features in common.
These converging aspects warrant the present work discussing more specifically the elements to
consider while designing experimental infections targeting ruminant host species. A particular
emphasis will be given to placental crossing and teratogenic potential of these two viruses.
2. Studying the Pathogenesis and Immune Response of BTV and SBV in Natural Ruminant Host
Species
Experimental infections of mammalian hosts proved to be a highly valuable tool to study
pathogenicity, virulence, pathogenesis, and transplacental infections since the dawn of the study of
infectious diseases [8]. Design of in vivo models evolved and were usefully complemented with
in vitro and in silico approaches to better comprehend the host-pathogen interactions.
Prior to study the pathogenesis of BTV and SBV in ruminants, including teratogenic potential,
experimental models reproducing the disease had to be found.
To date there are no lab-adapted colonies of Palearctic Culicoides. Given the feeding behaviour
of Culicoides, investigating the most adapted route of inoculation is of prime importance to ensure
standardization and repeatability of challenge experiments. Amongst other important pathogenesis
factors to consider when designing experimental infections, the origin of the inoculum and its
passage history has to be carefully evaluated. Indeed the number of passages, the cell culture system
used to grow the inoculum or by contrast, infectious blood or serum source are central to achieve
experimental infection matching virological, clinical, and serological parameters of field infection with
wild-type viruses.
2.1. Selection of an Appropriate Inoculum is Crucial to Achieve Adequate Experimental Infection
Adequate inoculum to use in infectious challenges in order to study viral pathogenesis should be:
(1) Safe, meaning it should have been screened for contaminations, adventitial agents or other
pathogens [9];
(2) Easily available, practical and standardised; and
(3) Made of a virus displaying similar replication and virulence properties than wild-type.
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2.1.1. Infectious Blood versus Cell Passaged Inoculum
A high quality infectious inoculum reproducing the pathogenesis of diseases was essential to
investigate vaccine efficacy requirements or certain specific aspects of the pathogenesis of recently
discovered viruses [10,11]. Facing an emerging disease with epizootic potential, reproduction of
clinical disease under experimental conditions might be more reliable using infectious animal products
such as blood or serum. Nevertheless, it appears that in the majority of the most recent experimental
infections involving BTV or SBV, cell culture grown inocula were preferred for challenges (Table 1).
Reasons to use cell-passaged viruses can be summarized as follow:
(1) Original isolate or any strain of particular interest can be shipped almost anywhere in the world,
leading to great improvement of standardization;
(2) Viral amplification by cell-passages allows a high increase in viral titre, subsequently allowing to
inoculate lower volumes;
(3) Screening for contamination or other pathogens is easier in cell culture and eliminate some
veterinary public health concerns about using ruminant blood to infect other ruminants; and
(4) Virulence in cell culture can be easily standardized.
Table 1. Inocula characteristics used in the 10 most recent experimental infection studies on BTV and
SBV (as searched on PubMed (July 2019) with keywords “experimental infection bluetongue” and
“experimental infection Schmallenberg”). Only articles about experimental infection involving at least
one ruminant species among cattle, sheep or goats were retained. The number of infected animals only
takes into account actually infected ones, excluding control animals.










BTV8 Cell-passaged 16 sheep KC 2 SC 1 105,75 Flannery et al., 2019 [12]
BTV4
TV16 Cell-passaged 6 sheep BHK21+KC not specified ID 1 10






Cell-passaged 30 cattle BHK-21 2-4 SC 2,5-4 106
Martinelle et al., 2018
[14]
BTV27 Cell-passaged blood(goat)
7 sheep, 13 goats
and 4 cattle
BSR;
ECE+BSR 3; 1+3 or 1+2
SC; IV
(blood)
2, 3 or 4;
1 (blood) 10
3–104.67 Bréard et al., 2018 [10]
BTV4 Cell-passaged 4 sheep, 3 goats and3 calves KC+BHK-21 1+1 SC 2 – 4 10
6 Schulz et al., 2018 [15]
BTV25 * Reverse genetic 10 sheep and 2 goats / / SC+IV 1 105 van Rijn et al., 2016 [16]
BTV8 Cell-passaged 8 calves BHK-21 2 SC+IV 1–4 104–106.15
Martinelle et al., 2016
[17]
BTV8 Cell-passaged 10 sheep and 4 cattle KC 2 SC, ID 1 107 Darpel et al., 2016 [18]
BTV8 Blood 8 sheep / / ID 2 106.08 Drolet et al., 2015 [19]
BTV8
BTV16 Cell-passaged 37 sheep KC 3 and 2 SC 3 not possible Bréard et al., 2015 [20]
SBV Cell-passaged 13 cattle BHK-21 4 SC 10 105
Ke˛sik-Maliszewska et
al., 2019 [21]






10 sheep, 9 cattle C6/36 1 SC 1 – 3 10
5.15 and
103.15**
Endalew et al., 2019 [23]
SBV Serum (cattle) 25 goats / / SC 1 / Laloy et al., 2017 [24]
SBV Plasma 9 sheep / / IV 20 not specified Rodríguez-Prieto et al.,2016 [25]
SBV Serum (cattle) 5 sheep / / SC 1 103.3 Poskin et al., 2015 [26]
SBV Serum (cattle) 17 sheep / / SC 1 103.3
Martinelle et al., 2015
[27]
SBV Serum (cattle) 9 sheep / / SC, ID, IN 1 103.3
Martinelle et al., 2015
[28]
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Table 1. Cont.










SBV Serum (cattle),blood (sheep) 6 goats / / SC 1 not specified Laloy et al., 2015 [29]
SBV Serum (cattle) 12 sheep / / SC 1 10
3.3, 102.3,
101.3 and 100.3
Poskin et al., 2014 [30]
*: actually BTV1 and BTV6 expressing BTV25 proteins. **: converted in TCID50/mL from PFU using the formula
PFU (mL)/TCID50 (mL) = 0.7 [31]. ID: intradermic; IN: intranasal; IV: intravenous; SC: subcutaneous.
In several recent studies [14] clinical signs reported in BTV infected animals were of a lesser extent
than those reported from the field [14,17,27,28,32–34]. As modified live vaccines gain their attenuation
through serial cell passages, the first and most obvious hypothesis to explain the mild severity of
bluetongue disease in the experiment is the use of culture grown virus. Moreover, passage history of
the inocula used involved mostly embryonated chicken eggs (ECE), BHK-21 and VERO cells. It was
reported that BTV grown on KC cells (derived from Culicoides sonorensis) could induce a greater clinical
signs severity [35] probably because KC cells better mimic natural vector-borne infection compared to
virus passaged on other cell lines [36].
Like other families of RNA viruses, Peribunyaviridae-RNA-dependent RNA polymerases and
orbiviruses VP1 RNA-dependent RNA polymerase are prone to produce errors during viral genome
replication. In general, RNA virus replication is characterized by high mutation rates (10−5–10−3
misincorporations per nucleotide copied), short generation times and high progeny yields [37]. In
addition, segmented RNA viruses also generate genomic variations through recombination and
reassortment [38]. Therefore, RNA viruses form populations of closely related viral variants that
started from a single clone: the quasispecies [39,40].
With arthropod vectors, SBV and BTV typically undergo an alternate two-host ‘life cycle’ and
are therefore suggested to be more stable and to evolve slower than vector-independent viruses [41].
Both steps may put selective pressures on these viruses, but it remains unknown whether sequence
divergence is related to the mammalian or arthropod portion of life cycle. However, it has been
demonstrated that despite the lack of changes in the consensus sequence, the passage of BTV in
Culicoides cells induces an increase of the number of low-frequency variants as well as an increase in
virulence [42]. This phenomenon has been hypothesized to explain the reduced viraemia and clinical
picture seen in the re-emerging BTV8 in 2017 versus the 2007 strain [12].
As a matter of fact, it was also reported that the inoculation of infectious material from field
isolates rarely produce a clinical picture as severe as in natural infection [19]. An additional hypothesis
would be that Culicoides saliva might act as a catalyser enhancing the ability of BTV to produce severe
clinical signs. Indeed Culicoides saliva was demonstrated to contain a trypsin-like protease able to
cleave VP2, leading to infectious subviral particles formation with enhanced infectivity [43].
We demonstrated the suitability of BTV8 passaged a few times on cell culture to both reproduce
clinical signs and RNA detection in calves [33]. Other authors concluded to the benefits of culture-grown
viruses to be used in experimental challenges in ruminants [44], as well. Despite converging results,
policy of the OIE remains unchanged regarding recommended vaccine efficacy requirements, i.e.,
challenging vaccinated and unvaccinated sheep with a virus “passaged only in ruminant animals and
with no or limited ECE or cell culture passages” [45].
Results regarding SBV do not show that much consistency. In cattle, Wernike et al. reported
a reduced viral replication of cell culture-grown SBV when compared to natural host-passaged
inoculum [46]. By contrast, one year later the same team concluded to the suitability of both infectious
serum and low passage cell culture material for SBV experimental challenges in sheep [47]. In addition
to the passage history, the origin of the isolated virus seems to be of importance as virus originating
from the central nervous system failed to reproduce RNAemia in inoculated animals [47]. Successive
serial passages in cell-culture usually result in decreased virulence. However, regarding SBV, Varela
et al. reported an increased pathogenicity in a SBV strain passaged 32 times in INF-incompetent
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sheep CPT-Tert cells, associated with a faster spread of the virus in the brain of suckling mice [48].
SBV was demonstrated to grow efficiently in several cell lines including sheep CPT-Tert, bovine
BFAE, human 293T, dog MDCK, hamster BHK-21, BSR, KC, and VERO cells [48,49]. Whereas serial
passages in CPT-Tert led to the accumulation of a variety of mutations mostly in the M and S segments,
the porcine cell line SK-6 proved to be highly susceptible and to allow the genetic stability of SBV
throughout successive passages [50]. Therefore, depending on the cell line used to grow SBV, serial
passages can lead to attenuation, increased virulence, or efficient propagation with a low frequency of
nucleotide exchanges.
2.1.2. A Matter of Doses and Routes
When it comes to arboviruses the choice of the route of inoculation can be driven by two main
considerations:
(1) The need for a route that best mimics the behaviour of the vector in field conditions. Usually
haematophagous arthropods are either telmophagous or solenophagous; depending on the
vector species the route might be intradermal (ID), subcutaneous (SC), or intravenous (IV). In
experimental infections the inoculated viral load and volume are usually higher than the ones
inoculated through naturally occurring feeding given the size of the arthropods and the size
of their mouthparts [51]. Another drawback already mentioned is the lack of vector saliva
components, which can modify the structure and infectivity of Reoviridae and Peribunyaviridae
viral particles [43,52].
(2) The need for a route that will ensure the virus to reach the blood stream. Quite obviously this is
the intravenous route. Since vector saliva components can enhance the infectivity of arboviruses
there is a risk that the inoculation of the virus alone or at a distal site from the vector feeding site
could result in a failed infection [53]. Therefore, the option to bypass the skin for reaching the
bloodstream may be relevant.
Several authors including us [17] used mixed routes to overcome the respective disadvantages of
each approach (Table 1; [34,54]). In a study of our group, we compared intranasal, intradermal and
subcutaneous routes for experimental infections of ewes with SBV [28]. Intradermal is an interesting yet
underused route: indeed most haematophagous arthropods do not pass the skin and their mouthparts
only allow them to feed intradermally. Most of the cellular and fluid exchanges between the skin
and the blood do occur in the dermis [55]. In addition, there are some evidences suggesting that
intradermal inoculation can be more appropriate to reproduces many aspects of natural infection,
including clinical disease, viral and immune responses [56]. The intradermic route was demonstrated
to better mimic natural early stages of the infection, directly influencing the severity of the disease.
BTV-induced immunosuppression is linked to the infection and disruption of follicular dendritic cells,
which is mostly possible through intradermic inoculation [57].
However, to perform an actual intradermal inoculation the volume to be injected has to be limited,
the dermis being mostly composed of a dense network of collagen fibres. Therefore, it is required
to multiply inoculation sites to reach desired total inoculum volume and infectious titre. To realize
the inoculation itself, the most practical tools are Dermojet® (Akra Dermojet) or special syringes for
intradermal injections (used to perform bovine tuberculosis skin tests for example). These devices
allow usually volumes between 0.1 and 0.4 mL, thus the need for multiple injections to reach the
common 1–4 mL inoculation volume used in ruminant infectious challenges experiments (Table 1).
Moreover, with both systems the inoculum has to be transferred from its original vial to a small tank of
the dermojet or to a special cartridge to be used with the intradermal syringe. This extra step increases
the number of handlings, which should be limited especially in the case of BSL3 pathogens.
We investigated the intranasal route to test whether or not a potential direct SBV contamination
between sheep could be achieved [28]. Regarding BTV several authors reported unexpected and
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inconclusive direct horizontal transmission with different serotypes (BTV8, BTV1, and BTV26 at
least) [58–61].
Several authors reported a direct link between the inoculated viral doses and the onset of clinical
signs and viraemia, i.e., the higher the dose the sooner the clinical signs and viral RNA detection [62–64].
In another study, we evaluated four 10-fold dilutions of a SBV infectious serum inoculum in ewes [30].
The undiluted original inoculum had a titre of 2 × 103 TCID50/mL. It appears there is a critical dose
to be inoculated for reproducing field-like virological and immunological parameters, and once this
threshold is reached, there is no dose-dependent effect anymore. In the successfully infected animals,
no statistical differences between the different inoculation doses were found in the duration or quantity
of viral RNA circulating in blood, nor in the amount of viral RNA present in virus positive lymphoid
organs. Likewise Di Gialleonardo et al. compared three groups of cattle inoculated with 100-fold
dilutions of BTV8; no significant differences in viraemia kinetics could be found [65].
Inoculation by the bite of Culicoides was reported to be more efficient than intradermal inoculation,
especially by delaying the early immune response of the host despite a generally lower inoculated viral
dose when compared to needle inoculation [66]. Several mechanisms were hypothesized to explain
this apparently enhanced infectivity in Culicoides transmitted BTV:
(1) The Culicoides saliva contains proteases able to cleave VP2, leading to the formation of infectious
subviral particles (ISVP) displaying higher infectivity in KC cells and Culicoides [43];
(2) The ratio of infectious BTV particles versus defective virions produced within Culicoides might
be higher when compared with cell culture grown BTV [66]; and
(3) Pharmacological agents contained in Culicoides saliva might affect the host’s immune response
by anti-proliferative effects on leucocytes [67] or a reduced INF alpha/beta expression, as
demonstrated with vesicular stomatitis virus and mosquito saliva [68].
Nonetheless, the use of Culicoides to perform experimental challenges remains highly limited by
practical constraints: to date besides C. nubeculosus, C. riethi, and C. sonorensis no other Culicoides species
were successfully establish as lab-adapted colonies [69,70], the alternative being insects caught in the
wild. In addition, prior to the infectious challenge on the ruminant host, the infection of Culicoides is
particularly tricky given the size of the insect and the exact amount of virus delivered to each ruminant
cannot be known.
Altogether, the subcutaneous route seems to represent the best compromise for BTV and SBV. The
dose itself has to be sufficient but there is no gain in using massive viral load.
2.1.3. Screening for Concomitant Pathogens
Bluetongue disease history is scarred with incidents of contamination of biological samples. In
1992, modified live vaccines against canine distemper, canine adenovirus type 2, canine parainfluenza,
and canine parvovirus, reconstituted with a killed canine coronavirus vaccine, led to abortions in
several bitches. A virus could be isolated and was eventually identified as BTV serotype 11 [71,72].
More recently, a case of BTV11 contamination was reported by ANSES (Agence nationale de sécurité
sanitaire de l’alimentation, de l’environnement et du travail, Maison-Alfort, France), in the context of an
experimental infection of goats with BTV8. It appeared to be very closely related to the BTV11 isolated
in Belgium [73]. We discussed a BTV15 contamination in a recent study [17]. This particular inoculum
has been previously involved in two other experimental infections. Eschbaumer et al. used BTV1
culture supernatant that was then passaged once on VERO cells before being injected in calves and
sheep [74]. That inoculum has been subsequently used by Dal Pozzo et al. [34], with the exact same
outcome, namely discovery of the BTV15 contamination. BTV inoculums were not only contaminated
with BTV heterologous serotypes: Rasmussen et al. reported the use of a BTV2 inoculum contaminated
with Border Disease Virus in sheep [75].
So far, literature does not report experimental infections with a SBV inoculum that was contaminated
by another virus belonging to the same or a different family. Broadly speaking contamination routes are
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most likely related to i) laboratory contamination during sample preparation or ii) natural multiple infection
of the original donor animal [76]. Given the potential dramatic consequences of such contamination
incidents, inocula should be tested for major pathogens affecting the host species used in challenge
experiments but also for a set of BTV serotypes considered to be the most at risk. Despite the transient
circulation of BTV6 [77], BTV11 [76], and BTV14 [78] of vaccine origin in Europe, the BTV11 contamination
here above mentioned happened to be similar to BTV11 reference strain. Hence, the contamination of the
inoculum is far from being necessarily related to an ongoing viral circulation even though it might remain
silent because of the lack of clinical consequences. Thus, to rule out any potential BTV contamination
all known BTV serotypes should be tested for. Such a recommendation would inevitably increase the
constraints and costs of quality control of inocula prior to their use in experimental infections. Extensive
screening could however be considered on a case-by-case basis.
3. BTV and SBV Display Placental Crossing Abilities and Teratogenic Potential
Vertical transmission from pregnant dams to their offspring is one of the major consequences
for both SBV and BTV. Many pathogens are able of crossing the placenta to cause foetal injury. Most
maternal virus infections are not transmitted to the foetus. However, certain viruses are able of crossing
the placental barrier possibly causing developmental defects (teratogenesis). The teratogenesis is the
production of a permanent abnormality in structure or function, restriction of growth, or death of the
embryo or foetus [79]. The outcome of in utero infection depends on the susceptibility of the foetus to
the infecting virus, which in turn, is a reflection of the gestational age of the foetus at exposure as well
as the virulence characteristics of the infecting virus [80]. Nervous tissues are important targets for
both BTV and SBV: usually the younger the foetus, the more severe the lesions [81,82].
To colonize the foetus viruses need a way in. Therefore, it is considered that SBV in utero infection
can only occur once the first placentomes were established, around day 30 of pregnancy in cattle and
slightly earlier in sheep [83–85]. At implantation, several changes occur: the papillae in the uterine
glands immobilize the conceptus and it starts to elongate (cattle: 15 days post coitum (dpc); sheep:
13-16 dpc). Subsequently the cells of the trophectoderm and the uterine epithelium get interdigitated
and binucleate cells start to be seen. Then binucleate cells start to differentiate and to migrate (cattle:
20-22 dpc; sheep: 16–18 dpc). Foetal villi develop in the caruncular areas starting at 24–26 dpc in
small ruminants and 28–30 dpc in cattle, thus defining the end of the implantation and the start of
the placental development [86]. Table 2 summarizes some of the essential events in the course of the
prenatal development in cattle and sheep.
Table 2. Key events in sheep and cattle embryos/foetuses with particular emphasis on nervous and
immune systems. Compiled from [87–93].
Event Timing in Cow (dpc) Timing in Sheep (dpc)
Blastocyst hatching from zona pellucida 9 9
Elongation of the blastocyst, establishment of the primitive streak,
emergence of the notochord 17–18 13–14
Appearance of neural folds, closure of the neural groove 17–19 15–16
Implantation begins 16–19 15–18
Neurula 20–21 17
Neural tube complete; optic and otic vesicles present 21–23 19–20
Placentation begins 22–23 17–22
Three brain vesicles visible 24–25 17
Placentoma are detectable 32–36 21
Lymphoid development of the thymus 42 36
Spleen development 55 43–44
Peripheral lymph nodes 60 45
IgM containing cells 59 65
Myelin sheath acquisition (starting) 60 54–63
IgG containing cells 145 87
With dpc, the days post coitum; IgM, immunoglobin M; IgG, immunoglobin G
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In a recent study, we decided to infect with BTV8 vaccinated and non-vaccinated pregnant heifers
at 120 days of pregnancy (BTV pregnant heifers study [32]). We also challenged pregnant ewes with
SBV at 45 and 60 days of pregnancy (SBV pregnant ewes study [27]). Thus, for both viruses the
experimental infection took place within the critical timeframe, between 30 and 150 days for cattle and
between 30 and 70 days of pregnancy for sheep (Figure 1, [85]). Moreover, in experimental conditions
the most frequent BTV transplacental infection was reported to occur at mid-term gestation, around 70
days of pregnancy in sheep [58,59].
The prenatal period can be divided into four main periods: i) fertilization; ii) blastogenesis; iii)
embryogenesis; and iv) foetogenesis [94]. The embryo develops tissues and organ structures from
the three original germ layers (ecto-, meso-, and endoderm). Once the organs are differentiated the
embryo becomes a foetus [95]. The foetal phase is characterized by a fast growth of the conceptus.
In cattle and sheep the foetogenesis starts around 45 and 38 dpc, respectively [90]. Thus, the critical
timeframe for BTV and SBV infection overlaps the end of the embryo stage and the beginning of the
foetal stage. Moreover, although in ruminants gamma globulins are unable to go through the placental
barrier from the mother to the foetus it is admitted that cow and sheep foetuses become sequentially
and increasingly immunocompetent to a larger variety of antigens throughout the pregnancy [96,97].
The critical timeframe for BTV and SBV infection also spans over the course of several important
events during the immune system development (Table 2). Although the sequence of antigens to be
successively and progressively recognized by the foetal ruminant through pregnancy seems to be quite
conserved between individuals, these antigens can be recognized starting with a difference of a few
days between individuals [98]. This individual variability could explain the findings by De Clercq et
al. (2008), who reported all possible combinations of serological status/RTqPCR results in dam/calf
pairs in a context of high BTV8 suspicion along with results which were interpreted as apparent
immunotolerance [99]. Likewise, malformed calves and lambs were reported to be SBV viropositive or
vironegative with or without SBV antibodies, suggesting the possibility of an in utero clearance of the
virus. Moreover, most of the malformed calves that were negative in both SBV antibodies and RTqPCR
were born from seropositive mothers [100].
In our studies, none of these evocative lesions was reported either in the BTV pregnant heifers
study or in the SBV pregnant ewes study [27,32].
Following the infection of pregnant dams we reported the reddening of the muzzle and
haemorrhages in the wall of the pulmonary artery in calves born from non-vaccinated mothers.
Haemorrhages of the pulmonary artery is a BTV typical yet not pathognomonic lesion [101]. These
findings were associated with the absence of any anti-BTV antibodies prior to the colostrum intake [32].
Melzi et al. reported the early infection and destruction of follicular dendritic cells following BTV
infection. Consequently, antibody production is notably impaired and could be an element explaining
the lack of BTV antibody detection in those calves [57]. This result provides an interesting perspective
to the many petechial haemorrhages we observed on lymph nodes in several of our own experimental
infections [14,17,32,33].
Following the infection of pregnant ewes with SBV, out of the 22 born-alive lambs none had any
anti-SBV neutralizing antibodies prior to colostrum intake [27].
In both these experiments, timing of inoculation was optimal to achieve transplacental infection
of the foetus with regard to data available from the literature yet no malformations could be seen.
No antibodies against the virus used to infect the mothers could be detected as well. These striking
results might even question the success of the infection, notwithstanding the positive RNA detection
in the mothers. In our BTV pregnant heifers study, the report of similar lesions and serology results in
another experiment on goats [102], and in our SBV pregnant ewes study the detection of SBV nucleic
acids in organs of several lambs and many extraembryonic structures provided support to an actual
transplacental infection. In addition, in another study [103] we managed to isolate SBV from foetal
envelopes in the animals from the SBV pregnant ewes study at birth, thus 90 and 105 days post infection.
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The very low ratio of precolostral seroconversion in immunocompetent foetuses was also reported
following the infection of pregnant cattle with SBV [104].
Transplacental transmission of BTV8 based on field data was reported to range from 16% [105,106]
to 35% [107,108]. In experimental infections, passage of BTV8 from the mother to the foetus could be
demonstrated in 43% of infected ewes whereas BTV1 could be detected in up to 67% of the foetus [59].
The highest susceptibility could be observed around 35-42 days of pregnancy in sheep [109] and
infections after day 75 were reported to result in much lighter consequences [110]. Placental crossing,
depending on the gestational stage, the BTV serotype and the inoculated dose, was reported to cause
congenital defect in up to 40% of the offspring of infected ewes [111]. Other authors observed a BTV8
vertical transmission rate of 33% in goats infected at 61 days of pregnancy [112].
During the BTV epizootic of 2007–2008, Darpel et al., estimated transplacental infection rate of
33%, which is consistent with the latter result [107].
The lesions potentially presented by the calves affected in utero by SBV could be distinguished
according to two entities: a hydrocephaly/hydranencephaly syndrome and a torticollis/arthrogryposis
syndrome. By analogy with Akabane virus the infection during the first 6 months seems to be critical:
an infection of the foetus between 76 and 104 days usually gives rise to hydranencephaly/porencephaly
type lesions, and from 103 to 174 it is predominantly arthrogryposis [113]. The latest lesions have
been observed for infection at 249 days of gestation and it appears that foetuses less than two months
old (after conception) could be protected from in utero infection [113]. In contrast to SBV torticollis
was hardly seen after a BTV8 in utero infection during the BTV epidemic in 2006–2009 but was more
dominated by hydranencephaly in sheep [114].
Also in contrast to SBV, BTV in utero infection is in the vast majority of cases associated to BTV
lab adapted strains (i.e., passaged on cell culture like modified live vaccine strains) or more recently
with the European BTV8 wild type virus. By the end of the 20th century, at least five BTV serotypes of
modified live vaccine origin (BTV4, BTV10, BTV11, BTV13, BTV17) were reported to be able to cross
the placental barrier and possibly causing teratogenic effects [115–118]. In utero infection caused by
wild-type strains was considered uncommon [119] yet documented [120].
SBV vertical transmission seems to be lower when compared to BTV, especially in cattle [121].
The rate of malformations caused by SBV was reported to be about 0.5% in cattle [122] although the
rate of intrauterine infection—based on serological results of the calves prior to colostrum intake—was
reported to be up to 28% [83]. Other authors documented field data about congenital malformations
affecting 3% of the calves but 8-10% of the lambs in farms at the beginning of the SBV epizootic [123,124].
In Belgium based on a survey targeting farmers we also found an estimated 10% of malformed sheep
in SBV positive flocks [125].
Table 3 summarizes the most common in utero malformations and nervous lesions induced by
some of the most common viruses inducing BTV and SBV-like lesions in ruminants.
Table 3. Summary of some of the most common central nervous and musculoskeletal lesions following
in utero infection with bovine virus diarrhoea virus (BVDV), SBV, BTV, Akabane virus (AKAV), or Aino
virus (AV). Adapted from [126].
Lesion Definition BVDV SBV BTV AKAV/AV
Hydranencephaly Extensive loss of cerebral tissue with replacement byclear fluid + + + +
Porencephaly Cystic fluid filled cavities in the brain tissue + + + +
Hydrocephalus Dilation of the lateral ventricles by cerebrospinal fluid + + + -
Microencephaly Reduced size of the cerebrum + + + +
Cerebellar
hypoplasia Reduced size of the cerebellum + + +
Kyphosis Dorsal vertebral column curvature - + - -
Lordosis Ventral vertebral column curvature - + - -
Scoliosis Lateral vertebral column curvature - + - -
Torticollis Twisted cervical vertebral column curvature - + - -
Arthrogryposis Joint contraction of the limbs - + +/- +
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Embryonic losses represent a key factor affecting ruminant production systems. In cattle, as well
as in sheep, most of the spontaneous embryo mortalities occur in the early embryonic life, namely
before 16–18 dpc [129,130]. In cattle early embryonic losses under normal conditions were reported to
range from 20 to 44% whereas in sheep in ranges from 12 to 30%, with a clear increase of embryo deaths
with the ovulation rate [129,131]. The impact of both BTV and SBV on reproductive parameters other
than teratogenesis is well documented. BTV8 was reported to increase the 56-days-return to service
rate and the number of AI (Artificial Insemination) required to achieve pregnancy [132,133]. During
the SBV epizootic the number of AI to get cattle pregnant was slightly yet significantly increased
regardless of whether or not they were part of a herd reporting malformations indicative of an actual
infection [134].
Although SBV and especially BTV had a tremendous economic impact on livestock industry, it is
worthwhile highlighting the relative poor efficiency of the placental crossing and more specifically the
overall low rate of congenital deformities induced by those viruses. However, congenital malformations
underestimate the actual rates of BTV and SBV transplacental infections [128].
4. Conclusion and Future Prospects
The number of ruminants used in experimental infections is chosen based on welfare and statistical
concerns but also quite unfortunately on economic and practical grounds [8]. We performed our
experimental infections with BTV in the BSL3 facilities of Sciensano (Ukkel, Belgium) and with SBV in
BSL2+/BSL3 facilities depending the phase of the experiment. Indeed, the Belgian Service of Biosafety
and Biotechnology as well as the Belgian law classify BTV as a class 3 pathogen whereas there is no
recommendation for SBV. Our biosafety measures for SBV were based on the analogy with AKAV, also
classified as a class 3 pathogen [135]. Domestic ruminants being herd animals, need to be housed in
groups or at least not individually. Euthanasia methods have to be the most humane as possible and
clear end points have to be defined. Given the scarcity of clinical signs caused by BTV and SBV in
the field and the individual variations in the response to the infection the number of animals to be
included has to be chosen very carefully to comply with the Reduction objective (Three Rs concept)
but has to be sufficient to limit the risk of not being able to provide useful data in the context of the
ongoing scientific investigation. This is particularly difficult for experimental infection of pregnant
ruminants with low malformation rates following transplacental transmission.
The most objective parameter to assess a vaccine efficacy against a virus and especially a RNA
vector-borne virus is the evaluation of the viral RNA detection by RTqPCR in the host target [44]. BTV
and SBV virulence was demonstrated to vary depending on the ruminant host whether it is cattle,
sheep or goat. In addition, pregnancy length differs between cattle and small ruminants while the
placentation and the development of the foetal envelopes present slight differences [136]. Consequently,
to study any of the specific aspects related to a ruminant species there are no other animal models or
any alternative able to mimic the natural situation in a proper way [8].
The results presented in our latest studies provide new insights in viruses that spread
through Europe causing severe losses in livestock industry. In addition, these aspects open new
perspectives to expand the knowledge on emerging vector-borne viruses targeting ruminants. More
specifically, according to our experiments, the subcutaneous route with an inoculum passaged a
limited number of times on cell culture seems to represent the best compromise between a high
probability to reproduce an infection similar to what happens in the field and logistics concerning the
preparation/storage/management of the inoculum. To prevent the loss of viral variability and limit the
risks of attenuation, isolation of BTV could be done on KC cells [35], whereas SBV could benefit from
an isolation on the highly susceptible SK-6 cell line [50]. Screening for concomitant pathogens should
be considered on a case by case basis, if required. The dose should be chosen based on literature data
yet no advantage is provided by inoculating a massive viral load.
Since some data from other authors suggest a better reproduction of the diseases with intradermal
inoculation, it could be further investigated, especially if more user-friendly devices would be available.
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A major breakthrough would be the successful adaptation of a colony of Palearctic BTV and SBV
vector Culicoides species (C. obsoletus/scoticus, pulicaris) to laboratory conditions and subsequent use
in infectious challenges. Vector-borne transmission of BTV implies the puncture of the skin at some
point. There is growing evidence that under certain circumstances additional routes of transmission
can be observed: a goat was reported to be infected by BTV2 without direct contact [75]. The recently
discovered BTV26 also displayed the ability to infect goats through direct contact [61]. In other
experimental infections control ewes were found positive with BTV1 and BTV8 [58,59]. The study
of the virus factors affecting this modified/underreported transmission feature should allow a better
understanding of the epidemiology of the disease.
In conclusion, targeting ruminant host species in experimental infections especially with BSL3
Culicoides borne pathogens is very expensive, time consuming, subject to stringent animal welfare
constraints and critical sample size analysis to meet optimal statistical requirements. However,
ruminant model remains unavoidable to assess the disease impact and to study the pathogenesis of
emerging vector-borne viruses.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/11/8/753/s1,
Figure S1: Schematic suggested timeframe for SBV (A) and BTV (B) in utero infection causing defects in cattle and
small ruminants’ offspring [27,32,81,85,104,127,128].
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